Status:
TERMINATED
Multicentre Registry of Treatments and Outcomes in Patients With Chronic Lymphocytic Leukaemia (CLL) Or Indolent Non Hodgkin's Lymphoma (iNHL)
Lead Sponsor:
Astellas Pharma International B.V.
Conditions:
Indolent Non Hodgkin's Lymphoma (iNHL)
Chronic Lymphocytic Leukaemia (CLL)
Eligibility:
All Genders
18+ years
Brief Summary
The purpose of this study is to document the pharmacological treatment strategies used in treatment naïve and previously treated relapsed/refractory iNHL/CLL patients in the Middle East and North Afri...
Detailed Description
Patients will be followed up to 30 months.
Eligibility Criteria
Inclusion
- Informed consent
- CLL patients or
- iNHL patients
- Clinical decision made to initiate or adapt treatment of CLL/iNHL("Need to treat")
Exclusion
- Patient deemed unfit for enrollment by the documented opinion of the investigator
- Watch and wait patients
- Richter's transformation
- Patients otherwise not eligible for (pharmacological) intervention
- Moribund patients
Key Trial Info
Start Date :
January 1 2015
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
August 1 2015
Estimated Enrollment :
25 Patients enrolled
Trial Details
Trial ID
NCT02273856
Start Date
January 1 2015
End Date
August 1 2015
Last Update
June 21 2016
Active Locations (8)
Enter a location and click search to find clinical trials sorted by distance.
1
Site JO96201 King Abdullah University Hospital
Irbid, Irbid Governorate, Jordan, 22110
2
Site KW96501 Kuwait Cancer Control Center
Ash Shuwaykh, Shuwaikh, Kuwait, 70653
3
Site Hammoud Hospital University Medical Center
Beirut, Beyrouth, Lebanon, 1600
4
Site Hotel Dieu De France
Beirut, Beyrouth, Lebanon, 166830